摘要
目的研究奈达铂联合紫杉醇同步放化疗治疗宫颈癌的临床疗效及安全性。方法选择宫颈癌患者作为研究对象,随机分为给予放疗联合奈达铂加紫杉醇化疗方案的观察组和放疗联合顺铂加紫杉醇化疗方案的对照组,观察肿瘤缓解情况、分期情况、疗效相关指标及安全性相关指标。结果观察组化疗缓解总有效率57.69%,TNMⅠ期2例、Ⅱ期6例、Ⅲ期11例、Ⅳ期7例,肿瘤缓解情况及分期情况均明显好于对照组;化疗效果指标VEGFB以及化疗安全性指标肾功能损害、肝功能损害、心功能损害例数明显低于对照组,sFlt-1水平明显高于对照组。结论奈达铂联合紫杉醇同步放化疗治疗能够有效的改善肿瘤分期和治疗效果,减少不良反应,具有积极的临床价值。
Objective To study the clinical efficacy and safety of Nedaplatin, paclitaxel combined with radiotherapy in treating cervical cancer. Methods Cervical cancer patients were collected as the research object and randomly divided into the observation group given nedaplatin, paclitaxel combined with radiotherapy and control group given cisplatin, pa- elitaxel combined with radiotherapy. Then tumor remission and stage condition, curative effect and safety related index were observed. Results The total efficiency of 57. 69% and 2 cases of TNM 1,6 cases of TNM II, 11 cases of TNM III and 7 eases of TNM IV of observation group were significantly better than control group ; chemotherapy effect index VEG- FA and security index renal function cases of damage, liver function damage, heart function damage were significantly lower than control group, the sFh - 1 level was significantly higher than control group. Conclusion Nedaplatin, paclita- xel combined with radiotherapy has positive clinical value for it can effectively improve the tumor stage and treatment effect, reduce adverse reaction.
出处
《医药论坛杂志》
2013年第12期41-43,共3页
Journal of Medical Forum
关键词
宫颈癌
化疗
奈达铂
安全性
Cervical cancer
Chemotherapy
Nedaplatin
Safety
